Literature DB >> 8736141

[Dystonias: clinical and therapeutic aspects in 64 patients].

J P De Mattos1, A L De Rosso, S Novis.   

Abstract

The experience with 64 patients with dystonia seen at the Extrapyramidal Diseases Sector of the Neurology Department of the Hospital Universitário Clementino Fraga Filho of the UFRJ is presented as well as the pertinent review of the literature. The five-and-a-half-year of follow-up showed that 33 were male and 31 female; 48 were white, 10 mulatto and 6 negro; the mean time of disease was 9 years and 8 months. According to the distribution of the movement disorder, 30 (46.9%) were focal, 17 (26.6%) segmental, 13 (20.3%) generalized, 3 (4.7%) hemidystonia and 1 (1.5%) multifocal. In 11 (17.2%) the age of onset was before 12 years old, in 6 (9.4%) between 13 and 20 years old, and in 47 (73.4%) after 20 years old. According to the etiology, 39 (60.9%) were idiopathic sporadic, 6 (9.4%) were idiopathic familial and 19 (29.7%) were symptomatic. The therapeutical approach used in these patients were anticholinergic drugs, dopaminergic agonists or antagonists and baclofen, alone or associated with anticholinergic drugs for generalized dystonia. The authors conclude that botulinum toxin type A is the most valuable therapeutic agent in the treatment of focal dystonia.

Entities:  

Mesh:

Year:  1996        PMID: 8736141     DOI: 10.1590/s0004-282x1996000100005

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  1 in total

1.  Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data.

Authors:  Hsin Fen Chien; Ana Lucia Zuma de Rosso; André Sobierajski Dos Santos; Carlos Roberto de Mello Rieder; Debora Palma Maia; Delson José da Silva; Marcio da Cunha Andrade; Marcus Vinicius Della Coletta; Maria do Desterro Leiros da Costa; Nasser Allam; Roberto César Pereira do Prado; Vanderci Borges; Vitor Tumas; Wagner de Goes Horta
Journal:  eNeurologicalSci       Date:  2016-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.